Financhill
Sell
17

EQ Quote, Financials, Valuation and Earnings

Last price:
$0.60
Seasonality move :
35.05%
Day range:
$0.58 - $0.61
52-week range:
$0.56 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.46x
P/B ratio:
0.90x
Volume:
100.6K
Avg. volume:
126.5K
1-year change:
-18.92%
Market cap:
$20.9M
Revenue:
$36.1M
EPS (TTM):
-$0.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EQ
Equillium
$11.6M $0.14 -100% -276.19% --
ATEC
Alphatec Holdings
$147.2M -$0.11 23.49% -83.35% $16.88
MDGL
Madrigal Pharmaceuticals
$34.4M -$6.91 -- -23.06% --
MTNB
Matinas BioPharma Holdings
-- -$1.06 -100% -45.83% --
SPRO
Spero Therapeutics
$7.7M -$0.36 -100% -505.55% $5.00
TNON
Tenon Medical
$1.3M -$6.16 11.51% -60.9% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EQ
Equillium
$0.59 -- $20.9M -- $0.00 0% 0.46x
ATEC
Alphatec Holdings
$9.34 $16.88 $1.3B -- $0.00 0% 2.29x
MDGL
Madrigal Pharmaceuticals
$308.71 -- $6.7B -- $0.00 0% --
MTNB
Matinas BioPharma Holdings
$0.55 -- $2.8M -- $0.00 0% 0.60x
SPRO
Spero Therapeutics
$0.96 $5.00 $52.3M 12.00x $0.00 0% 0.58x
TNON
Tenon Medical
$1.85 -- $5.8M -- $0.00 0% 0.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EQ
Equillium
-- 8.502 -- 2.90x
ATEC
Alphatec Holdings
100.26% -0.009 66.79% 1.02x
MDGL
Madrigal Pharmaceuticals
13.09% 3.388 2.53% 5.79x
MTNB
Matinas BioPharma Holdings
-- 6.772 -- --
SPRO
Spero Therapeutics
-- 2.060 -- 2.64x
TNON
Tenon Medical
-- -0.884 -- 3.16x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EQ
Equillium
-- -$679K -20.35% -20.35% -0.06% -$7.7M
ATEC
Alphatec Holdings
$102.7M -$30.7M -33.31% -1019.24% -21.95% -$25.2M
MDGL
Madrigal Pharmaceuticals
$60M -$116.3M -74.25% -89.04% -166.12% -$67.8M
MTNB
Matinas BioPharma Holdings
-- -$4.4M -- -- -- -$3.5M
SPRO
Spero Therapeutics
-- -$18.6M 4.36% 4.36% -237.79% $12.8M
TNON
Tenon Medical
$418K -$3.2M -400.82% -430.31% -358.96% -$2.4M

Equillium vs. Competitors

  • Which has Higher Returns EQ or ATEC?

    Alphatec Holdings has a net margin of -0.06% compared to Equillium's net margin of -26.29%. Equillium's return on equity of -20.35% beat Alphatec Holdings's return on equity of -1019.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    ATEC
    Alphatec Holdings
    68.16% -$0.28 $526.4M
  • What do Analysts Say About EQ or ATEC?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Alphatec Holdings has an analysts' consensus of $16.88 which suggests that it could grow by 80.68%. Given that Equillium has higher upside potential than Alphatec Holdings, analysts believe Equillium is more attractive than Alphatec Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    ATEC
    Alphatec Holdings
    6 1 0
  • Is EQ or ATEC More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.386, suggesting its more volatile than the S&P 500 by 38.566%.

  • Which is a Better Dividend Stock EQ or ATEC?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or ATEC?

    Equillium quarterly revenues are $12.2M, which are smaller than Alphatec Holdings quarterly revenues of $150.7M. Equillium's net income of -$7K is higher than Alphatec Holdings's net income of -$39.6M. Notably, Equillium's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 2.29x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    ATEC
    Alphatec Holdings
    2.29x -- $150.7M -$39.6M
  • Which has Higher Returns EQ or MDGL?

    Madrigal Pharmaceuticals has a net margin of -0.06% compared to Equillium's net margin of -172.04%. Equillium's return on equity of -20.35% beat Madrigal Pharmaceuticals's return on equity of -89.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    MDGL
    Madrigal Pharmaceuticals
    96.54% -$4.92 $894.2M
  • What do Analysts Say About EQ or MDGL?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 20.83%. Given that Equillium has higher upside potential than Madrigal Pharmaceuticals, analysts believe Equillium is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    MDGL
    Madrigal Pharmaceuticals
    0 0 0
  • Is EQ or MDGL More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

  • Which is a Better Dividend Stock EQ or MDGL?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or MDGL?

    Equillium quarterly revenues are $12.2M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Equillium's net income of -$7K is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Equillium's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    MDGL
    Madrigal Pharmaceuticals
    -- -- $62.2M -$107M
  • Which has Higher Returns EQ or MTNB?

    Matinas BioPharma Holdings has a net margin of -0.06% compared to Equillium's net margin of --. Equillium's return on equity of -20.35% beat Matinas BioPharma Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    MTNB
    Matinas BioPharma Holdings
    -- -$0.85 --
  • What do Analysts Say About EQ or MTNB?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 5404.59%. Given that Matinas BioPharma Holdings has higher upside potential than Equillium, analysts believe Matinas BioPharma Holdings is more attractive than Equillium.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    MTNB
    Matinas BioPharma Holdings
    0 0 0
  • Is EQ or MTNB More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.222%.

  • Which is a Better Dividend Stock EQ or MTNB?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or MTNB?

    Equillium quarterly revenues are $12.2M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. Equillium's net income of -$7K is higher than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Equillium's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.60x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    MTNB
    Matinas BioPharma Holdings
    0.60x -- -- -$4.3M
  • Which has Higher Returns EQ or SPRO?

    Spero Therapeutics has a net margin of -0.06% compared to Equillium's net margin of -219.3%. Equillium's return on equity of -20.35% beat Spero Therapeutics's return on equity of 4.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    SPRO
    Spero Therapeutics
    -- -$0.32 $65.5M
  • What do Analysts Say About EQ or SPRO?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 421%. Given that Equillium has higher upside potential than Spero Therapeutics, analysts believe Equillium is more attractive than Spero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    SPRO
    Spero Therapeutics
    1 2 0
  • Is EQ or SPRO More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

  • Which is a Better Dividend Stock EQ or SPRO?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or SPRO?

    Equillium quarterly revenues are $12.2M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Equillium's net income of -$7K is higher than Spero Therapeutics's net income of -$17.1M. Notably, Equillium's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.58x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    SPRO
    Spero Therapeutics
    0.58x 12.00x $7.8M -$17.1M
  • Which has Higher Returns EQ or TNON?

    Tenon Medical has a net margin of -0.06% compared to Equillium's net margin of -358.96%. Equillium's return on equity of -20.35% beat Tenon Medical's return on equity of -430.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    TNON
    Tenon Medical
    47.13% -$29.04 $8.2M
  • What do Analysts Say About EQ or TNON?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Tenon Medical has an analysts' consensus of -- which suggests that it could grow by 332.43%. Given that Equillium has higher upside potential than Tenon Medical, analysts believe Equillium is more attractive than Tenon Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    TNON
    Tenon Medical
    0 0 0
  • Is EQ or TNON More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Tenon Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock EQ or TNON?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Tenon Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or TNON?

    Equillium quarterly revenues are $12.2M, which are larger than Tenon Medical quarterly revenues of $887K. Equillium's net income of -$7K is higher than Tenon Medical's net income of -$3.2M. Notably, Equillium's price-to-earnings ratio is -- while Tenon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.18x for Tenon Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    TNON
    Tenon Medical
    0.18x -- $887K -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 3.65% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 4.9% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock